An open label phase II study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (EPOC2301)
2025 · ESMO Gastrointestinal Oncology · 0 citations
https://doi.org/10.1016/j.esmogo.2025.100267